Posted by Michael Wonder on 04 Apr 2019
Ondine Biomedical receives fast track designation from the U.S. FDA for nasal photodisinfection system
3 April 2019 - Ondine Biomedical today announced that the U.S. FDA has granted fast track designation to its fixed-dose combination product for the prevention of post-surgical staphylococcal infections.
The same fixed-dose combination product was recently also designated as a qualified infectious disease product by the FDA.
Ondine's nasal photodisinfection system is a first-in-class, light-activated, non-antibiotic, antimicrobial therapy developed to eradicate a broad spectrum of nasal pathogens without promoting antibiotic resistance, including the 'superbug' methicillin-resistant Staphylococcus aureus.
